During the past decade, MidAmerica Cancer Care conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "MidAmerica Cancer Care" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "GORTEC (Head and Neck Oncology and Radiotherapy Group)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "MidAmerica Cancer Care" are "Myelofibrosis" (3 trials), "Post Essential Thrombocythemia Myelofibrosis" (2 trials), "Post Polycythemia Vera Myelofibrosis" (2 trials), "Primary Myelofibrosis" (2 trials) and "Neuroendocrine Tumors" (1 trials). Many other conditions were trialed in "MidAmerica Cancer Care" in a lesser frequency.

Most popular intervention types in "MidAmerica Cancer Care" are "Drug" (6 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "parsaclisib" (2 trials), "placebo" (2 trials), "ruxolitinib" (2 trials), "Berzosertib" (1 trials) and "Cisplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "MidAmerica Cancer Care" are 6 trials for "All" genders.

Currently, there are NaN active trials in "MidAmerica Cancer Care". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in MidAmerica Cancer Care, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MidAmerica Cancer Care, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".